Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin

Stanley S SchwartzDiabetes Disease Management at the University of Pennsylvania, Penn Presbyterian Medical Center, Philadelphia Heart Institute, Philadelphia, Pennsylvania, USAAbstract: Insulin resistance and impaired beta-cell function are primary defects that occur early in the course of developme...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Stanley S Schwartz
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/1fcb56dee5e6455b8c0b71ae2b8348d7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1fcb56dee5e6455b8c0b71ae2b8348d7
record_format	dspace
spelling	oai:doaj.org-article:1fcb56dee5e6455b8c0b71ae2b8348d72021-12-02T02:02:02ZPioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin1178-7007https://doaj.org/article/1fcb56dee5e6455b8c0b71ae2b8348d72010-07-01T00:00:00Zhttp://www.dovepress.com/pioglitazone-for-the-treatment-of-type-2-diabetes-in-patients-inadequa-a4818https://doaj.org/toc/1178-7007Stanley S SchwartzDiabetes Disease Management at the University of Pennsylvania, Penn Presbyterian Medical Center, Philadelphia Heart Institute, Philadelphia, Pennsylvania, USAAbstract: Insulin resistance and impaired beta-cell function are primary defects that occur early in the course of development of type 2 diabetes. Insulin resistance leads to hyperinsulinemia in order to maintain normal glucose tolerance. In most cases of type 2 diabetes, beta-cell dysfunction develops subsequent to the development of insulin resistance, and it is not until such beta-cell dysfunction develops that any abnormality in glucose tolerance is seen. Insulin resistance is a primary defect in type 2 diabetes. The risk of coronary heart disease is significantly increased in patients with type 2 diabetes. Cardiovascular disease causes 80% of all diabetic mortality, and in 75% of those cases, it is a result of coronary atherosclerosis. These points provide a rationale for early and aggressive management of cardiovascular risk in patients with diabetes. Thiazolidinediones represent an effective tool for targeting some features of this increased risk as they decrease insulin resistance and can prevent and/or delay diabetes progression.Keywords: pioglitazone, type 2 diabetes, insulin Stanley S SchwartzDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2010, Iss default, Pp 243-252 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Specialties of internal medicine RC581-951
spellingShingle	Specialties of internal medicine RC581-951 Stanley S Schwartz Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin
description	Stanley S SchwartzDiabetes Disease Management at the University of Pennsylvania, Penn Presbyterian Medical Center, Philadelphia Heart Institute, Philadelphia, Pennsylvania, USAAbstract: Insulin resistance and impaired beta-cell function are primary defects that occur early in the course of development of type 2 diabetes. Insulin resistance leads to hyperinsulinemia in order to maintain normal glucose tolerance. In most cases of type 2 diabetes, beta-cell dysfunction develops subsequent to the development of insulin resistance, and it is not until such beta-cell dysfunction develops that any abnormality in glucose tolerance is seen. Insulin resistance is a primary defect in type 2 diabetes. The risk of coronary heart disease is significantly increased in patients with type 2 diabetes. Cardiovascular disease causes 80% of all diabetic mortality, and in 75% of those cases, it is a result of coronary atherosclerosis. These points provide a rationale for early and aggressive management of cardiovascular risk in patients with diabetes. Thiazolidinediones represent an effective tool for targeting some features of this increased risk as they decrease insulin resistance and can prevent and/or delay diabetes progression.Keywords: pioglitazone, type 2 diabetes, insulin
format	article
author	Stanley S Schwartz
author_facet	Stanley S Schwartz
author_sort	Stanley S Schwartz
title	Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin
title_short	Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin
title_full	Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin
title_fullStr	Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin
title_full_unstemmed	Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin
title_sort	pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/1fcb56dee5e6455b8c0b71ae2b8348d7
work_keys_str_mv	AT stanleysschwartz pioglitazoneforthetreatmentoftype2diabetesinpatientsinadequatelycontrolledoninsulin
_version_	1718402761658204160

Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin

Ejemplares similares